C ell metabolism involves a highly coordinated set of activities in which multienzyme systems cooperate to convert nutrients into building blocks for macromolecules, energy currencies and biomass 1, 2 . In cancer, genetic or epigenetic changes can perturb the activity of key enzymes or rewire oncogenic pathways, resulting in cell metabolism alterations 3, 4 . Specific metabolic dependencies in cancer have also been the basis for effective therapeutics, including inhibitors that target IDH1 as well as folate and thymidine metabolism 5 . The search for new drug targets, however, has been hampered at least in part by the fact that cancer metabolomic studies often draw conclusions from small numbers of cell lines, and, therefore, making generalizations is difficult. In contrast, there have been no systematic profiling efforts that encompass hundreds of cellular and genetic contexts. Furthermore, there is no high-throughput methodology that assesses cancer metabolic needs by perturbing related pathways across many cell lines. Consequently, the discovery of new anti-cancer metabolic targets might benefit from high-quality, comprehensive metabolomic data in addition to the current CCLErelated characterization that includes genomic, transcriptomic features as well as genetic dependency maps [6] [7] [8] [9] .
C ell metabolism involves a highly coordinated set of activities in which multienzyme systems cooperate to convert nutrients into building blocks for macromolecules, energy currencies and biomass 1, 2 . In cancer, genetic or epigenetic changes can perturb the activity of key enzymes or rewire oncogenic pathways, resulting in cell metabolism alterations 3, 4 . Specific metabolic dependencies in cancer have also been the basis for effective therapeutics, including inhibitors that target IDH1 as well as folate and thymidine metabolism 5 . The search for new drug targets, however, has been hampered at least in part by the fact that cancer metabolomic studies often draw conclusions from small numbers of cell lines, and, therefore, making generalizations is difficult. In contrast, there have been no systematic profiling efforts that encompass hundreds of cellular and genetic contexts. Furthermore, there is no high-throughput methodology that assesses cancer metabolic needs by perturbing related pathways across many cell lines. Consequently, the discovery of new anti-cancer metabolic targets might benefit from high-quality, comprehensive metabolomic data in addition to the current CCLErelated characterization that includes genomic, transcriptomic features as well as genetic dependency maps [6] [7] [8] [9] .
Results
Profiling metabolites from cultured CCLE cell lines. 928 cancer cell lines from 20 major cancer types were cultured in vitro for metabolomic profiling of 124 polar and 101 lipid species (Fig. 1a) . Extracted polar and lipid metabolites were analyzed using hydrophilic interaction chromatography and reversed phase chromatography (Fig. 1b) . Sample measurements were obtained in four batches using pooled lysates as references to ensure consistent data quality. Trend normalization methods were applied before performing global comparisons. To assess experimental variation for each metabolite, we estimated a coefficient of variation (CV) based on 14 cell lines with biological replicates and found that 221 out of 225 metabolites had CV < 0.1 (Extended Data Fig. 1a ), indicating reproducible estimates for most profiled metabolites. The complete metabolomic data and CV values are in Supplementary Table 1 .
Next, we evaluated the metabolic similarities among cell lines using hierarchical clustering. The two main clusters strongly correlated with hematopoietic versus non-hematopoietic lineages, suggesting major metabolic differences in these two groups (P < 1 × 10 −10 , Fisher's exact test) (Extended Data Fig. 1b) . To further quantify the degree that metabolite levels (y) associate with major cancer lineages (X), we adopted a linear regression model (Methods). The result showed that 148 out of 225 metabolites had a lineage effect (defined as r 2 ) greater than 0.1 (Extended Data Fig. 1c and Supplementary Table 1 ), suggesting that for these metabolites, at least 10% of the cross-cell-line metabolite level variances were related to lineage. To obtain lineage-specific distributions, we estimated the average abundance for each metabolite in major cancer lineages (Supplementary Table 1 ). This approach leads to a quantitative, cross-lineage view of metabolite levels in model cancer cell lines. For example, phosphocreatine accumulates in esophagus cell lines but not in kidney or hematopoietic lineages (Extended Data  Fig. 1d ). In contrast, 1-methylnicotinamide is highly abundant in most kidney and pleura cell lines but is lower in many other lineages with multiple outliers (Extended Data Fig. 1e ). These data suggest that lineage distinctions exist in model cancer cell lines and can influence cross-cell-line metabolic comparisons.
Interrogating metabolite associations with genetic features. In addition to lineage events, genetic or epigenetic events in cancer are likely to alter cellular metabolism. In order to identify metabolic variation that might be attributable to genetic differences, we curated a matrix of genetic features including 705 gene . T statistics were calculated by linear regression for each metabolite paired with each feature across all cell lines conditioned on the major lineages and were used to represent the regression coefficients scaled by standard deviations. Examples mentioned in the text are magnified and shown in black boxes. CN, copy number. d, 2HG and the top correlated mutations among all mutational features. Cell lines are shown as lines and are ordered by increasing levels of 2HG. Those cell lines with corresponding mutations are labeled shown in black. The reported test statistics and P values are based on the significance tests of genetic feature regression coefficients (cell line n = 927, two-sided t tests). e, Cancer cell lines with outlier levels of 2HG have specific IDH1/2 mutations. f, Malate levels and a heat map representation of top correlated copy number alterations among all copy number features. The features are color-coded to indicate various copy number alterations (log 2 scale) and are standardized for plotting. The reported test statistics and P values are based on the significance tests of genetic feature regression coefficients (cell line n = 912, two-sided t tests). g, Schematic of the genomic locus containing ME2, ELAC1, and SMAD4. mutations and 61 amplifications or deletions. To look for associations between these genetic features and metabolite levels, linear regression models controlling for lineage effects were applied ( Fig.  1c and Methods). The genetic features were scored by associations with each metabolite and can be compared in the order of statistical significance (Supplementary Table 2 ). Interestingly, we found that mechanistically relevant features often displayed strong correlations with aberrant metabolite levels. The selected examples are discussed below.
First, our unbiased comparison revealed the expected finding that for 2-hydroxyglutarate (2HG), the IDH1 hotspot missense mutation was a top predictive genetic feature (Fig. 1d) . Cell lines with an aberrant accumulation of this metabolite are mostly IDH1 or IDH2 mutants (IDH1/IDH2; Fig. 1e ), recapitulating the known relationship 10, 11 . Notably, although there are no known IDH1/IDH2 mutants in the CCLE renal cell carcinoma lines, additional lineage effect analysis revealed that on average, renal cell carcinoma cells had a threefold higher level of 2HG than other cell lines (Supplementary Table 1 ). This finding is consistent with the observation of increased 2HG in renal cell carcinoma tumors 12 . Our analysis also showed KEAP1 mutation as the genetic feature most strongly associated with glutathione (GSH/GSSG) and NADP + (Extended Data Fig.  2a and Supplementary Table 2 ). On average, cancer cell lines with mutated KEAP1 had approximately twofold higher levels of these redox metabolites (Extended Data Fig. 2b ), suggesting a gain of buffering abilities against oxidative stresses 13, 14 . Unlike the strong associations seen with KEAP1 and IDH1 alterations, it is noteworthy that a number of common oncogenic events including EGFR, KRAS, NRAS, TP53, PTEN, and TSC1/2 had weak to nonsignificant associations with the profiled metabolites when queried using unbiased analysis (Extended Data Fig. 2c -h and Supplementary Table 2) .
In copy-number space, using malate as an example, we showed that the most strongly associated features are deletions of ELAC1 and ME2 (Fig. 1f and Supplementary Table 2 ). These genes are colocalized in a 0.4 Mb region surrounding the tumor suppressor gene SMAD4 on chromosome 18 and are frequently co-deleted (Fig. 1g) . ME2 (malic enzyme 2) catalyzes the oxidative decarboxylation of malate to pyruvate. Its mRNA levels were abolished in cells harboring homozygous deletion (Extended Data Fig. 2i ), resulting in a correlation with higher malate levels (Extended Data Fig. 2j ). Although ME3 was previously found to be synthetic lethal with this deletion event 15 , we did not observe greater ME3 dependency in cancer cells with ME2 loss based on current CRISPR-Cas9 data in the cancer dependency map 16 (Extended Data Fig. 2k ). To summarize, this resource enables unbiased association analysis between metabolites and various genetic features and confirms previous findings linking oncogenic changes (for example, IDH1, KEAP1, ME2) to aberrant metabolite levels.
DNA methylation regulates metabolite abundances. Next, we examined DNA methylation and assessed the associations with the metabolite levels. 2,114 genes whose mRNA transcripts were significantly associated with their promoter CpG methylation levels were included in this analysis, given that these selected genes were likely to be regulated via DNA methylation. Systematic analysis of the correlates revealed a surprising number of specific alterations related to potential metabolic dysregulation ( Fig. 2a and Supplementary Table 2 ). These observations can be classified into two classes. First, DNA hypermethylation appears to influence metabolite levels by suppressing certain metabolite degradation pathways. For example, SLC25A20 methylation was strongly correlated with the accumulation of long-chain acylcarnitine species (for example, oleylcarnitine) (Fig. 2b) . SLC25A20, also known as carnitine/acylcarnitine translocase, shuttles acylcarnitines across the mitochondrial inner membrane for fatty acid oxidation 17 . SLC25A20 hypermethylation correlated with marked mRNA transcript reduction (Fig. 2c) , which was associated with significantly elevated levels of acylcarnitine species having acyl chains of 14, 16 or 18 carbons (Fig. 2d-g ), but not with other acylcarnitine species with shorter or longer acyl chains (Extended Data Fig. 3a-j) , indicating an unusual specific fatty acid catabolism defect in these cell lines. Second, DNA hypermethylation appears to regulate metabolite levels by limiting components of biosynthetic pathways. For example, reduced proline levels were associated with the hypermethylation of PYCR1, which encodes an enzyme converts pyrroline-5-carboxylate to proline (Fig. 2h,i) . Additionally, decreased alanine levels were associated with the hypermethylation of GPT2, which that synthesizes alanine via transamination (Fig. 2j,k) . Both of these effects were particularly strong among hematopoietic cell lines. Taken together, these findings show that this resource provides an unbiased way to assess the impact of DNA methylation events in regulating intracellular metabolite concentrations.
Metabolite-dependency association analysis. There has been a longstanding desire to take therapeutic advantage of dysregulated cancer metabolic states. To this end, we sought to link metabolic alterations to cancer vulnerabilities unveiled in the DepMap CRISPR-Cas9 knockout dataset, in which 483 CCLE cell lines have been screened with a library of ~74,000 sgRNAs targeting ~17,000 genes 16 . CERES scores were used to summarize gene-level dependency (small values indicate greater sensitivity to gene knockout) 16 and then each gene-level dependence was queried with respect to metabolite alterations. This unbiased metabolite-dependency association analysis shows that the dissimilar metabolic phenotypes observed in cancer cell lines are paired with distinct gene dependencies and, therefore, potential therapeutic targets ( Fig. 3a and Supplementary Table 3 ). Here, we focus on the top 3,000 dependent genes (Methods) and highlight representative examples in metabolism related to redox balance, amino acids and lipids. First, as expected, aberrant accumulation of redox metabolites including GSH, GSSG and NADP + (partly attributed to KEAP1 mutation, vide supra) was associated with increased sensitivity to knockout of NFE2L2 (NRF2), a transcription activator involved in antioxidant response ( Fig. 3b-d) . Notably, the most associated dependency was SLC33A1 (Fig. 3b-d) , an acetyl-CoA transporter whose role in redox homeostasis is currently unknown. As another example, we found that cells with lower asparagine levels were more dependent on its synthetase (ASNS) (explored further below) and EIF2AK4 (GCN2, involved in amino acid starvation response) (Fig. 3e) . Furthermore, we also observed an interesting association involving two distinct triacylglycerol (TAG) clusters (Fig. 3a) . One cluster consisted of polyunsaturated TAG species (at least four total carbon-carbon double bonds from three acyl chains), and the other cluster consisted of less-unsaturated TAG species, including monounsaturated fatty acyls (MUFA) (Fig. 3a) . To classify cancer cell lines enriched with either cluster, we labeled them as polyunsaturated fatty acyl high (PUFA high , n = 315) or polyunsaturated fatty acyl low (PUFA low , n = 325) after excluding those with nonsignificant lipid unsaturation differences (Fig. 3f ). This unsaturation difference also existed in other lipid species such as phosphatidylcholines ( Fig. 3g ) and cholesterol esters (Fig. 3h) . We asked whether this distinct lipid utilization pattern might link to targetable dependencies. By comparing CERES scores, we found that the PUFA high cell lines were sensitive to the knockout of GPX4 (Fig. 3i) , which mediates the detoxification of peroxidized PUFA 18 . In contrast, PUFA low cell lines were sensitive to the loss of CTNNB1 or SCD (Fig. 3i) , which synthesizes MUFA. Together, these unbiased association analyses suggest that cancer cell lines cultured in vitro have significant lipidomic differences that can be selectively targeted based on PUFA classifications.
Phenotypic profiling of barcoded CCLE lines. As shown in the results described above, lower asparagine levels strongly associated with increased sensitivity to loss of asparagine synthetase (ASNS) (Fig. 3e) . The non-essential amino acid asparagine is synthesized by ASNS but can also be imported directly from the media. We showed that ASNS knockdown significantly impeded cell proliferation when media asparagine was limiting (Extended Data Fig.  4a,b) . Given that some CCLE cell lines with ASNS promoter hypermethylation have aberrantly low ASNS expression, even in the presence of its transcriptional activator ATF4 (Fig. 4a and Extended Data Fig. 4c,d ), we hypothesized that intrinsic methylation-dependent gene suppression might be selectively targeted using specific nutrient deprivation. To explore this, we used a variation of the PRISM technology in which 544 adherent CCLE lines labeled with 24-nucleotide barcodes were grown in a pooled format 19 (Fig. 4b ). The mixed cell pools were cultured under specific media conditions with defined amino acid concentrations, and relative cell viability was then estimated via high-throughput sequencing of the barcode collected after 6 d of treatment (Supplementary Table 4 ). Here, we found that when the pooled cell populations were grown under limiting asparagine conditions, those with aberrantly low expression of ASNS were selectively depleted ( Fig. 4c and Supplementary Table 4 ). In parallel, PRISM experiments were conducted in which arginine and glutamine (also non-essential amino acids; Extended Data Fig. 4e ) were set to different concentrations. Similarly, we found that lower expressions of ASS1 and GLUL (influenced by promoter region methylation) marked cells that were more sensitive to reduced supplies of arginine and, to a lesser degree, glutamine (Fig. 4d,e, Extended Data Fig. 4f,g and Supplementary Table  4) . Notably, in the case of glutamine dependency, we also observed a strong correlation with the proliferative doubling rate (Extended Data Fig. 4h ). Taken together, these examples suggest that DNA hypermethylation influences dependency on nutrient availability as exemplified by asparagine, arginine, and glutamine auxotrophy in subsets of cancer cell lines.
Expanding the therapeutic use of asparaginase. Whereas arginine and glutamine dependence across cell lines manifested as a graded response, the pronounced, nearly binary differences to asparagine depletion between cell lines with lower intrinsic expression of ASNS and the non-sensitive lines (Fig. 4c) prompted us to explore the potential therapeutic value of asparaginase beyond its use in treating acute lymphoblastic leukemia (ALL). We confirmed that cells with ASNS hypermethylation also lacked protein expression (Fig. 5a-c) and were profoundly sensitive to asparaginase in vitro (Fig. 5d) . To determine whether this dependence could be reproduced in vivo, we then subcutaneously implanted 7 × 10 6 of 2313287 (ASNS high) or SNU719 (ASNS low) cells into both flanks of nude mice. After the tumors reached about 100-200 mm 3 in volume, we then treated the mice with intraperitoneal injections of asparaginase (3,000 units/kg/ injection, five times per week) or vehicle control and monitored the tumor growth over a 3-week period. Here we observed a significant decrease of growth for SNU719 tumors but not 2313287 tumors, with little body weight loss ( Fig. 5e and Extended Data Fig. 5a,b) . We also showed that ASNS hypermethylation and loss of expression was maintained during implantation and treatment of these xenografts ( Fig. 5f and Extended Data Fig. 5c,d ). These data also suggest that ASNS immunohistochemistry (IHC) might be applied to stratify and select patients for asparaginase trials. To define the relevant patient population based on data from human tumor samples, we examined DNA methylation among gastric and hepatic cancers in The Cancer Genome Atlas (TCGA) and found it to be significantly associated with reduced ASNS expression in tumor samples (Fig.  5g) . Collectively, these results suggest that asparaginase can suppress the growth of defined subsets of cancer cell lines with loss of ASNS expression both in vitro and in vivo.
The landscape of kynurenine metabolism in the CCLE. In addition to analyzing metabolites with nutritional value, we also explored the patterns of signaling metabolites, including kynurenine. Kynurenine is produced from catabolism of tryptophan and can exert immunosuppressive effects through the aryl hydrocarbon receptor (AHR), leading to suppressed effector T cell proliferation and enhanced regulatory T cell generation [20] [21] [22] . These findings have led to clinical trials of IDO1 inhibitors targeting the kynurenine pathway in combination with PD1 blockade 23 . In the CCLE, we observed a wide range of intracellular kynurenine concentrations spanning three orders of magnitude across multiple cancer types (Fig. 6a) . We found that higher intracellular kynurenine levels were strongly associated with greater secretion into the media in both a discovery (NCI60, ref. 24 ) and a validation set of cell lines (Fig. 6b) . These data suggest that cell lines with higher intracellular kynurenine concentrations are also actively secreting it into the extracellular space.
We next asked whether kynurenine levels have a direct impact on cell proliferation rates by applying increasing concentrations of kynurenine to the pooled, barcoded CCLE lines. A weak to moderate decrease of growth was observed in most lines and was not correlated with the intrinsic synthesis capability (Extended Data Fig. 6a and Supplementary Table 4 ), suggesting that kynurenine does little to accelerate cell proliferation in vitro.
Notably, both indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are enzymes that catalyze the conversion of tryptophan to N-formylkynurenine, a precursor of kynurenine (Extended Data Fig. 6b) . By correlating mRNA transcripts (n = 18,205) with kynurenine levels, we found that IDO1, IDO2, and TDO were top hits that correlated significantly with kynurenine levels ( Fig. 6c and Extended Data Fig. 6c ). Interestingly, we observed abundant intracellular kynurenine in cell lines with high IDO1, IDO2, or TDO mRNA levels ( Fig. 6d and Extended Data  Fig. 6d) . By classifying the cancer cell lines harboring high levels of kynurenine based on their expression of IDO (IDO1 as the major form) versus TDO, we found that about one-third of cell lines have simultaneous IDO1 and TDO expression, and the rest are driven by either IDO1 or TDO (Fig. 6e) . This divergent expression pattern was also observed in different tumor samples in TCGA (Fig.  6f) . This finding suggests that cancer cells can probably use either enzyme or potentially both to produce kynurenine. We next asked whether the IDO1 selective inhibitor epacadostat is effective in blocking kynurenine secretion in these distinct settings. To test this idea in vitro, we profiled epacadostat dose-dependent suppression of kynurenine secretion in three representative cell lines. We found that epacadostat completely inhibited kynurenine secretion in NCIH596 (IDO1 high ), caused a major decrease of kynurenine secretion in IGR39 (IDO1 high + TDO high ) but had little impact on JHH7 (TDO high ) (Fig. 6g) . Therefore, these data linking high kynurenine to IDO1 or TDO mRNA expression suggest that selective IDO1 inhibition might only work in a subset of these tumors and could be further subject to escape mediated by TDO. Recently, negative phase III data were reported for the combination of epacadostat with the anti-PD1 antibody pembrolizumab in unselected patients with metastatic melanoma 25 . Our data raise the possibility that selecting patients with increased tumor production of kynurenine coupled with an understanding of which enzymes are producing kynurenine might be critical to further IDO and TDO inhibitor development.
Discussion
Cancers are diverse in histology, in the pattern of underlying genetic alterations and in metabolic signatures. To date, there has been no systematic metabolomic profiling for hundreds of model cancer cell lines from multiple lineages with distinct genetic backgrounds. To bridge this gap, we profiled 225 metabolites in a collection of 928 cancer cell lines and intersected this data with other large-scale profiling datasets. This breadth and depth allow various metabolic signatures to be probed in an unbiased manner and for metabolites with similar patterns to be identified. Beyond the diversity revealed in baseline metabolite levels, we also investigated the diverse proliferative responses to perturbations in the dynamic metabolic networks with pooled screens of 554 barcoded cell lines. Overall, the data and analyses suggest that distinct metabolic phenotypes exist in cancer cell lines at both the unperturbed and the perturbed states and that such phenotypes have direct implications for therapeutics targeting metabolism.
We delineated prevalent DNA methylation events in addition to somatic mutations and copy number alterations in various metabolic pathways and began to unveil their key regulatory roles both at the basal state and in the dynamics of cell growth. On one hand, gene hypermethylation events probably influence baseline metabolite abundance via reductions in key enzymes mediating metabolite degradation (for example, SLC25A20 with long-chain acylcarnitines) or synthesis (PYCR1 with proline, GPT2 with alanine). Alternatively, methylation-dependent suppression of gene expression can have profound modulatory effects in cell proliferation under altered nutrient conditions (for example, ASNS with asparagine, ASS1 with arginine).
In this resource, several observations relate to potential therapeutic applications. The observation of distinct associations between IDO and TDO enzymes and elevated levels of kynurenine suggests that clinical testing of either AHR inhibitors or dual IDO-TDO inhibitors might benefit from patient stratification based on kynurenine levels and the relative contribution of specific enzymes involved in its synthesis. Additionally, the suppressed ASNS expression in subsets of stomach and liver cancers raise the possibility of repurposing asparaginase as a therapeutic option for subpopulations in these diseases. Although asparaginase is an effective agent used in the regimen for ALL 26 , there has been no evidence for its potential efficacy for solid tumors in the clinic. This is consistent with our observation of abundant ASNS baseline expression in most lineages except the ALL, in which expression of ASNS is low (Extended Data Fig. 4c ). This underlying intrinsic dependence sharply contrasts with the studies combining ASNS inhibition with asparagine depletion in solid tumors 27, 28 . Consequently, our study of asparaginase use in treating solid tumors with intrinsic loss of ASNS may have therapeutic implications.
Several limitations of our study should be considered and improved in future large-scale metabolomic profiling efforts. First, only one biological replicate was used for most cell lines profiled, except for quality control (QC) purposes. Although QC measures have been implemented and multiple analyses demonstrated the rich information in this dataset, noise from multiple sources still exists, and additional biological replicates would improve data quality. Second, we expect that a broader collection of metabolites would generate information about a larger array of biochemical pathways. Third, because of the scale of these studies, we were unable to use dynamic measures of metabolic flux, and thus, we can only look at the steady-state levels of various metabolites profiled. Finally, the media used in tissue culture remain significantly different from in vivo environments. Consequently, large-scale metabolomic characterization of tumor samples will be an important next step.
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Methods
Cell lines and culture conditions. Human cancer cell lines were collected as described previously 7 . SNP genotyping was incorporated at each stage of cell culture to validate the identity of cell lines. The associated tissue type and gender information was annotated based on literature or vendor information when available. The cell culture media used in this study with catalog information are included in Supplementary Table 1. All cell lines were grown in T75 flasks with respective media using standard cell culture conditions (37 °C, 5% CO 2 ) and were free of microbial contamination, including mycoplasma. For each actively growing cell line with a low passage number, 2 million cells were seeded per T75 flask, the metabolites were extracted after 2 d and before the cells reached a confluence of 90%. Separate flasks were used for polar metabolite or lipid extractions.
Polar metabolite extraction. LC-MS grade solvents were used for all of the metabolite extraction in this study. For adherent cells, the media were aspirated off as much as possible, and the cells were washed with 4 ml cold PBS (no Mg 2+ / Ca 2+ ). After vacuum aspiration of PBS, the metabolites were extracted by adding 4 ml 80% methanol (−80 °C) immediately and the samples were transferred to a −80 °C freezer. The flasks were kept on dry ice during the transfer and were incubated at −80 °C for 15 min. Then, the lysate was collected by a cell scraper and transferred to a 15 ml conical tube on dry ice. The insoluble debris was removed via centrifugation at 3,500 r.p.m. for 10 min (4 °C). The supernatant was transferred to a new 15 ml conical tube on dry ice, and the tube with the pellet was kept for further extraction. Then, 500 μl 80% methanol (−80 °C) was added to each pellet. The mixture was resuspended by vortexing or pipetting and transferred to a 1.5 ml centrifuge tube on dry ice. The cell debris was removed by centrifuging samples at 10,000 r.p.m. for 5 min (4 °C). The supernatant was transferred to the corresponding 15 ml conical tube on dry ice so that all extracts were combined. The pooled extracts were stored at −80 °C before LC-MS analysis.
For cells growing in suspension, they were centrifuged to pellet at 300g for 5 min (4 °C), and the supernatant was then aspirated off as much as possible. These cells were washed once with 4 ml cold PBS (no Mg 2+ /Ca 2+ ) and then pelleted at 300g for 5 min (4 °C). After vacuum aspiration of PBS, the metabolites were extracted by adding 4 ml 80% methanol (−80 °C) immediately, and the samples were then transferred to a −80 °C freezer after brief vortexing. The samples were kept on dry ice during the transfer and were incubated at −80 °C for 15 min. The insoluble debris was removed by centrifuging at 3,500 r.p.m. for 10 min (4 °C). The subsequent steps were the same as those used for adherent cell lines. ). After vacuum aspiration of PBS, the lipid metabolites were extracted by adding 4 ml isopropanol (4 °C), and the lysate was collected by a cell scraper and transferred to a 15 ml conical tube on ice. The samples were covered to avoid exposure to light and were allowed to sit for 1 h at 4 °C. Samples were then vortexed and the cell debris was removed by centrifuging at 3,500 r.p.m. for 10 min (4 °C). The supernatant was transferred to a new 15 ml centrifuge tube on ice and stored at −20 °C before LC-MS analysis.
For cells growing in suspension, they were centrifuged to pellet at 300g for 5 min (4 °C) and the supernatant was then aspirated off as much as possible. These cells were washed once with 4 ml cold PBS (no Mg 2+ /Ca 2+ ) and they were pelleted at 300g for 5 min (4 °C). After vacuum aspiration of PBS, the lipid metabolites were extracted by adding 4 ml isopropanol (4 °C) immediately. After brief vortexing, the samples were covered to avoid exposure to light and were allowed to sit for 1 h at 4 °C. The insoluble debris was removed by centrifuging at 3500 rpm for 10 min (4 °C). The supernatant was transferred to a new 15 ml centrifuge tube on ice and stored at −20 °C before LC-MS analysis.
LC-MS instrumentation and methods.
A combination of two hydrophilic interaction liquid chromatography (HILIC) methods, either acidic HILIC method with positive-ionization-mode MS, or basic HILIC method with negative-ionization-mode MS was used to profile polar metabolites. Reversed phase chromatography was used to profile lipid species. The LC-MS methods were based on a previous study 29 , where the metabolite retention time and the selected reaction monitoring parameters were also described. LC-MS related reagents were purchased from Sigma-Aldrich if not specified. Pooled samples composed of 11 cell lines from different lineages were used for trend and batch correction.
The LC-MS system for the first method consisted of a 4000 QTRAP triple quadrupole mass spectrometer (SCIEX) coupled to an 1100 series pump (Agilent) and an HTS PAL autosampler (Leap Technologies). Polar metabolite extracts were reconstituted with acetonitrile/methanol/formic acid (74.9:24.9:0.2 v/v/v) containing stable isotope-labeled internal standards (0.2 ng/μl valine-d8 (Isotec) and 0.2 ng/μl phenylalanine-d8 (Cambridge Isotope Laboratories)). The samples were centrifuged (10 min, 9,000g, 4 °C), and the supernatants (10 μl) were injected onto an Atlantis HILIC column (150 × 2.1 mm, 3 μm particle size; Waters Inc.). The column was eluted isocratically at a flow rate of 250 μl/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 1 min followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 min. The ion spray voltage was set to 4.5 kV and the source temperature was set to be 450 °C.
The second method using basic HILIC separation and negative ionization mode MS detection was established on an LC-MS system consisting of an ACQUITY UPLC (Waters Inc.) coupled to a 5500 QTRAP triple quadrupole mass spectrometer (SCIEX). Polar metabolite extracts spiked with the isotope-labeled internal standards including 0.05 ng/μL inosine-15 N 4 , 0.05 ng/μL thymine-d 4 , and 0.1 ng/μL glycocholate-d 4 (Cambridge Isotope Laboratories) were centrifuged (10 min, 9,000g, 4 °C), and 10 μL supernatants were injected directly onto a Luna NH2 column (150 × 2.0 mm, 5 μm particle size; Phenomenex) that was eluted at a flow rate of 400 μL/min with initial conditions of 10% mobile phase A (20 mM ammonium acetate and 20 mM ammonium hydroxide in water (VWR) and 90% mobile phase B (10 mM ammonium hydroxide in 75:25 v/v acetonitrile/methanol (VWR)) followed by a 10-min linear gradient to 100% mobile phase A. The ion spray voltage was set to be −4.5 kV and the source temperature was set to be 500 °C.
Lipids were profiled using a 4000 QTRAP triple quadrupole mass spectrometer (SCIEX) coupled to a 1200 Series Pump (Agilent Technologies) and an HTS PAL autosampler (Leap Technologies). Lipid extracts in isopropanol, spiked with an internal standard (0.25 ng/μL 1-dodecanoyl-2-tridecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids)), were centrifuged and 10 μL supernatants were injected directly to a 150 × 3.0 mm Prosphere HP C4 column (Grace) for reversed phase chromatography. Mobile phase A was 95:5:0.1 (v/v/v) 10 mM ammonium acetate/methanol/acetic acid. Mobile phase B was 99.9:0.1 (v/v) methanol/acetic acid. The column was eluted isocratically with 80% mobile phase A for 2 minutes, followed by a linear gradient to 80% mobile phase B over 1 minute, a linear gradient to 100% mobile phase B over 12 minutes, and then 10 minutes at 100% mobile phase B. MS analyses were carried out using electrospray ionization and performed in the positive-ion mode with Q1 scans. Ion spray voltage was set to be 5.0 kV, and the source temperature was set to be 400 °C.
Generation of isogenic cell lines. A2058 cells were maintained in DMEM, supplemented with 10% FBS and 2 mM glutamine. 1% nonessential amino acids (NEAA, BioConcept, 5-13K00) was added if stated. This NEAA mix (100 × ) contained 10 mM of l-asparagine, l-alanine, l-aspartic acid, l-glutamic acid, l-proline, l-serine, and glycine. shRNA (Control_KD: AGAAGAAGAAATCCGTGTGAA, ASNS_KD1: GCATCCGTGGAAATGGTTAAA; ASNS_KD2: CATTCAGGCTCTGGATGAAGT; PLK1_KD: GGTATCAGCTCTGTGATAACA) were cloned in inducible pLKO-based lentiviral vectors (puromycin resistant). Wild type A2058 was infected with shRNA-expressing viruses respectively. After selection, the KD efficiency was evaluated by western blots upon 3 days of treatment with doxycycline (100 ng/ml).
Pooled screens of barcoded CCLE lines. The CCLE lines were barcoded and screened as described previously 19 . Briefly, cells were mixed as individual pools (~24 lines in each) and kept frozen in liquid nitrogen before use. On the day of experiment, the individual pools were mixed together in corresponding media conditions with equal numbers so that each line started from about 200 cells per T25 flask. After 6 d, the genomic DNA was extracted, and the barcodes were amplified by PCR before high-throughput sequencing. Three biological replicates were used in each condition, and the growth changes were calculated with the control conditions as reference.
Animal studies. The animal work was approved by the Institutional Animal Care and Use Committee (IACUC) at the Broad Institute. 4-week-old, female, athymic nude mice (CrTac:NCr-Foxn1 nu , Taconic) were inoculated subcutaneously with 7 × 10 6 cancer cells in phenol red-free RPMI media with 50% Matrigel in both flanks. The mice were randomized into the treatment or control group when tumors reached approximately 100-200 mm 3 in size. Asparaginase (Abcam) was delivered via intraperitoneal injection at 3,000 units/kg in 200 μl PBS 5 times per week (omitting Wednesday and Sunday) for 3 weeks. Tumor tissues were collected and processed for IHC staining via standard methods. All IHC staining was performed on the Leica Bond automated staining platform. Polyclonal Asparagine Synthetase (ASNS) antibody from Proteintech (#14861-1-AP) was run at 1:1,500 dilution using the Leica Biosystems Refine Detection Kit with citrate antigen retrieval. Tumor sizes were calculated by 1/2 × length × width × width.
Quantification of kynurenine secretion. To validate kynurenine secretion in the validation set of cell lines, cells were seeded on 6-well plates at a density of 4 × 10 5 /2 ml RPMI (+10% FBS) per well. The 16 cell lines included SNU719, WM793, LOXIMVI, UACC257, U2OS, JHH5, JHH4, SNU601, SNU668, NUGC3, 2313287, NCIH2196, NCIH596, JHH7, IGR39 and NCIH2228. The supernatant was collected 3 d later and the cell protein mass was measured by BCA assay. To profile kynurenine secretion in response to epacadostat, cells were seeded at a density of 25,000/125 μl/well in 96-well plates. Compounds were added at seeding, and supernatants were collected 3 d after. Secreted kynurenine in the conditioned media was quantified using a kynurenine ELISA kit (Rocky Mountain Diagnostics, Inc) according to manufacturer's protocol. RPMI (+10% FBS) was used as the negative control to determine background signal levels in the ELISA assay.
Analysis of DNA methylation. The CCLE reduced representation bisulfite sequencing (RRBS) data were used for gene methylation analysis. For independent validation and cell lines not covered (for example, JHH5, JHH6), genomic DNA from cell line or tumor samples was isolated and bisulfite converted using the EpiTect Fast LyseAll Bisulfite Kit (Qiagen) following manufacturer's instructions. For methylation-specific PCR, the primer set consisted of 5′CGTATTGAGACGTAAGGCGT3′ and 5′CTAACTCCTATAACGCGTACGAAA3′. For bisulfite sequencing, the primer set consisted of 5′GTTAGAATAGTAGGTAGTTTGGG3′ and 5′AAAATACACATATAACATTTACAAAAACTC3′. Purified PCR products were cloned into the pCR 4-TOPO TA vector using TOPO TA Cloning Kit (Invitrogen).
Statistical analysis. All statistical analyses used in this paper were done in R v 3.4.2 (downloaded from https://www.r-project.org/). Data visualization was done in R and Prism (GraphPad). Statistics and relevant information including the type and the number of replicates (n), the adopted statistical tests, and P values are reported in the figures and associated legends. For Pearson correlations, we used the cor.test function in R to conduct significance test and obtain the P values (two-sided). We used the Benjamini-Hochberg procedure to control for multiple hypothesis testing when applicable.
Metabolite data acquisition and quality control. Raw data were processed using MultiQuant 1.2 software (SCIEX) for automated LC-MS peak integration. All chromatographic peaks were also manually reviewed for the quality of integration and compared against known standards for each metabolite to confirm identities. Internal standard peak areas were monitored for quality control and to assess system performance over time. Additionally, pooled samples composed of mixed metabolites from 11 cell lines (NCIH446, DMS79, NCIH460, DMS53, NCIH69, HCC1954, CAMA1, KYSE180, NMCG1, UACC257 and AU565) were used after every set of 20 samples. This was an extra quality control measure of analytical performance and served as a reference for scaling raw metabolomic data across samples. The peak area for each metabolite in each sample was standardized by computing the ratio between the value observed in the sample and the value observed in the "nearest neighbor" pooled sample. These ratios were then multiplied by the mean value of all reference samples for each analyte to obtain standardized peak areas.
To remove potential batch effects, the ratio between the mean standardized peak area for each metabolite in a given batch and the mean standardized peak area for that metabolite across all the batches was computed. Then the standardized peak areas for that metabolite in that given batch were divided by that ratio. These standardized peak areas are included in Supplementary Table 1 . Note that the abundance of different metabolites cannot be compared given the nature of the LC-MS methods. Only for the same metabolite, the levels could be compared between different cell lines. The final batch-corrected standardized peak areas were then log 10 transformed. Additionally, considering the cell line to cell line variation in biomass that could contribute to systematic differences in metabolite abundance detected by LC-MS, we processed the data by two steps. First, we calibrated each column of metabolites to have the same median. Then we calibrated each row (cell line) to have the same median. Empirically, this median normalization step effectively calibrated metabolomic datasets, adjusting artificial differences due to different sample biomass before metabolite extraction. The final metabolomic data matrix (928 rows of cell lines and 225 columns of metabolites) for downstream analyses or modeling is included in Supplementary Table 1 .
Missing data handling. For the trend-corrected metabolomic dataset, a small fraction of values were missing. We first applied imputations using fully conditional specification implemented by the Multivariate Imputation via Chained Equations (MICE) algorithm from R package "mice", which has the advantage of preserving intrinsic data matrix structure and information. The quality of predictive mean matching-based imputations was inspected using diagnostic tools in the package. We noticed that the generated multiple matrices had negligible differences for most downstream applications due to the small fraction (9%) of missing values and the strong signals from observed values. Therefore, we chose one representative imputed matrix for downstream regression analysis that required a complete data structure for efficient computation.
Other cancer cell line dataset acquisition. The CCLE datasets (for example, mutation, copy number variation, RNA-seq) were downloaded from the CCLE portal (https://portals.broadinstitute.org/ccle). The CRISPR-Cas9-based geneessentiality data used (CERES scores, 2019Q1 release) were obtained from the Cancer Dependency Map project 16 (https://depmap.org/portal/; https://doi. org/10.6084/m9.figshare.5319388.v2).
Clustering and heat map plotting. Clustering was done in R with the function hclust. Note that each feature (for example, metabolite) was scaled to have mean 0 and standard deviation 1 before hierarchical clustering analysis and heat map plotting. The dissimilarity was defined as 1 minus the Pearson correlation between each pair of selected features. The resulting distance matrix was processed by the "centroid" method in the hclust function to get the clustering results. For heat map plots, we used the heatmap.2 function in the R package gplots.
Metabolite lineage effect analysis. To evaluate the association between the metabolite levels and the lineage types, we applied a linear regression model. We coded the lineage types as binary covariates (X). Cell lines were represented by the rows, with 1 indicating presence of the corresponding feature. Each metabolite level (log 10 scale) was used as the response variable Y. The calculated r 2 was used to characterize the lineage effects quantitatively.
Genetic, epigenetic, and dependency feature collection. We curated genetic and epigenetic features in our association analysis with CCLE metabolites. These included all nonsynonymous mutations of 474 cancer-related genes, deleterious, loss-of-function mutations of 202 genes, and hotspot missense mutations of 29 genes (TCGA hotspot count ≥10; https://portals.broadinstitute.org/ccle). Such discrete features were converted to binary indicators (1/0) in our analysis. We also selected 40 genes with frequent deletions and 21 genes with frequent amplifications. These copy number alteration events were validated to significantly associate with corresponding gene transcriptional levels (CCLE RNA-seq data). Additionally, the methylation scores of 2,114 genes were included given their significant negative associations with the corresponding transcriptional levels (CCLE RNA-seq data). To select dependencies, we focused on top 3,000 genes ordered by variance of CERES scores across the panel of cell lines. Genes with less cell-line-to-cell-line dependency difference (for example, non-essential) were not prioritized for metabolite-dependency association analysis.
Linear regression analysis. We applied a linear regression model to evaluate associations between two different datasets of CCLE cell lines (for example, genetic feature vs metabolite level). We included lineage variables to account for lineage-associated confounding effects when cell lines from different lineages were analyzed together.
First, we constructed a covariate matrix with cell lines as rows and features as columns for the linear regression. In addition to the intercept variable I, we also included binary variables indicating major lineages. Here, L1, L2,…, L17 represented the lineages of lung, large intestine, blood, urinary, bone, skin, breast, liver, ovary, esophagus, endometrium, central nervous system, soft tissue, pancreas, stomach, kidney, and upper aerodigestive tract. We further added variable (X) to this covariate matrix: each mutation variable was binary-coded; each continuous variable (for example, mRNA log 2 RPKM) was rescaled to have mean 0 and standard deviation 1.
The dependent variable vector Y could be another type of cell features. The coefficient vector was represented as β. For example, to answer the question that in a given cell line feature matrix (for example, collections of genetic or epigenetic features) which feature was the most associated with a given metabolite vector under the condition of controlled lineage effects, this regression analysis was applied to individual features (for example, individual genetic and epigenetic features) before comparisons. The calculated T statistics, P values, and estimated coefficients for X (β X ) were reported to evaluate the associations. All studies must disclose on these points even when the disclosure is negative.
Extended Data

Sample size
Sample sizes were determined on the basis of previous studies that used similar sample sizes to successfully detect a difference between groups.
Data exclusions There was no data exclusion.
Replication
The findings were reproduced with corresponding biological and technical replicates (indicated in the paper).
Randomization Cells or animals were randomized to control or treatment groups.
Blinding
The investigators were not blinded to animal group allocation. Human research participants were not used in this study. Blinding was not possible for animal studies, as animals were segregated into distinct, labeled cages according to the treatment group.
April 2018
validated with genetic perturbation shown in Extended Data Fig. 4 . 
Eukaryotic cell lines
Mycoplasma contamination
The cell lines were tested to be free of microbial contamination including mycoplasma.
Commonly misidentified lines
(See ICLAC register)
There are no commonly misidentified cell lines used in this study to our knowledge.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals 4-week-old, female, athymic nude mice (CrTac:NCr-Foxn1nu) were purchased from Taconic.
Wild animals
This study did not involve wild animals.
Field-collected samples
This study did not involve field-collected samples.
